期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 909, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ejphar.2021.174404
关键词
Immune checkpoint inhibitor; NSCLC; Adverse events; Nanomedicine
资金
- Shahid Beheshti University of Medical Sciences (Tehran, Iran)
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer with a poor prognosis. Immunotherapy, particularly immune checkpoint inhibitors, has shown promising results in improving survival rates of NSCLC patients. However, over-stimulation of the immune system via this therapy can lead to adverse events, highlighting the need for caution. Nanomedicine plays a significant role in enhancing tumor treatment by increasing drug concentration at the tumor site while minimizing side effects.
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer with the highest mortality rate and a poor 5-year survival rate. The majority of the cases are diagnosed in advanced stages when the disease has spread, which makes the tumor inoperable. Due to the antigenic essence of lung tumor cells, immunotherapy is a novel area and has exhibited remarkable results in this malignancy. Immune checkpoint inhibitors are inhibitory molecules that disrupt immune checkpoint signaling pathways whether in the immune cells or tumor cells. Tremelimumab and ipilimumab (CTLA-4 blockers), pembrolizumab and nivolumab (PD-1 blockers), and durvalumab, avelumab, and atezolizumab (PD-L1 blockers) are FDA-approved and improve the survival and objective response of NSCLC patients. Despite this, over-stimulation of the immune system via the immune checkpoint therapy is a double-edged sword that causes a spectrum of adverse events from moderate to lifethreatening. Nanomedicine considerably impacts the way of diagnosis and treatment of tumors to overcome treatment-related challenges. Accordingly, nanoparticle-based immune checkpoint inhibitor therapy increases the local concentration of immune checkpoint inhibitors while reduces the side effects, which result in boosting the anti-tumor immunity against various types of malignancies, including NSCLC. The current review provides comprehensive information about immune checkpoint therapy in NSCLC, their efficacy, and their safety profile. Besides, recent advances in nanoparticle-based immune checkpoint therapy and its limitation are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据